Product Information
IMIPRAMINE HCL 50 MG TABLET is a generic product labeled by Strides Pharma Inc., priced at $0.1557 per EA under NDC 64380017102. Its NADAC has been published 222 times since Jul 6, 2022.
FDA first approved this application on Oct 21, 1983. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50 mg/1
Manufacturer
Strides Pharma Inc.NDC
64380017102
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IMIPRAMINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA088276FDA Approved
10/21/1983
TE Code
AB
On Market Since
4/11/2022
Pharmacological Classes
Price Statistics
The NADAC for IMIPRAMINE HCL 50 MG TABLET has been published 222 times since Jul 6, 2022, and over the history we have for it it has declined 9.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1557 per EA |
|---|---|
| All-time high | $0.1716 (Jul 13, 2022) |
| All-time low | $0.0932 (Nov 20, 2024) |
| 52-week high | $0.1685 |
| 52-week low | $0.1240 |
| Median price | $0.1324 |
| Average price | $0.1327 |
| Largest weekly change | +30.3% (Nov 22, 2023) |
| Weeks tracked | 222 |
| Tracking since | Jul 6, 2022 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Imipramine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tricyclic Antidepressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IMIPRAMINE HCL 50 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for IMIPRAMINE HCL 50 MG TABLET, manufactured by Strides Pharma Inc., is $0.1557 per EA (NDC 64380017102), effective Sep 30, 2026.
How has the price of IMIPRAMINE HCL 50 MG TABLET changed over time?
Over the history we have for it, the NADAC for IMIPRAMINE HCL 50 MG TABLET has declined 9.3%. It has been tracked across 222 weekly CMS publications since Jul 6, 2022.
What are the highest and lowest recorded NADAC prices for IMIPRAMINE HCL 50 MG TABLET?
Since Jul 6, 2022, the NADAC for IMIPRAMINE HCL 50 MG TABLET has ranged from a low of $0.0932 (Nov 20, 2024) to a high of $0.1716 (Jul 13, 2022), with a median of $0.1324 per EA.
Are there cheaper alternatives to IMIPRAMINE HCL 50 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as IMIPRAMINE HCL 50 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures IMIPRAMINE HCL 50 MG TABLET?
IMIPRAMINE HCL 50 MG TABLET (NDC 64380017102) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.